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Abstract
Background: Kin17 is ubiquitously expressed at low levels in human tissue and participates in DNA replication, DNA repair
and cell cycle control. Breast cancer cells are characterized by enabling replicative immortality and accumulated DNA
damage. However, whether kin17 contributes to breast carcinogenesis remains unknown.
Methodology/Principal Findings: In this study, we show for the first time that kin17 is an important molecule related to
breast cancer. Our results show that kin17 expression was markedly increased in clinical breast tumors and was associated
with tumor grade, Ki-67 expression, p53 mutation status and progesterone receptor expression, which were assessed in a
clinicopathologic characteristics review. Knockdown of kin17 inhibited DNA replication and repair, blocked cell cycle
progression and inhibited anchorage-independent growth, while increasing sensitivity to chemotherapy in breast cancer
cells. Moreover, kin17 silencing decreased EGF-stimulated cell growth. Furthermore, overexpression of kin17 promoted DNA
replication and cell proliferation in MCF-10A.
Conclusions/Significance: Our findings indicate that up-regulation of kin17 is strongly associated with cellular proliferation,
DNA replication, DNA damage response and breast cancer development. The increased level of kin17 was not only a
consequence of immortalization but also associated with tumorigenesis. Therefore, kin17 could be a novel therapeutic
target for inhibiting cell growth in breast cancer.
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Introduction
Breast cancer is the most commonly diagnosed cancer and the
second leading cause of cancer-related death among women [1].
Although progress has been made in reducing the incidence and
mortality of breast cancer, disseminated metastasis still remains
incurable [2]. Furthermore, a number of early-stage breast cancer
patients relapse, regardless of the adjuvant treatment given. Substantial
efforts have been made to understand the molecular bases of the disease
to support new discoveries in early detection and effective treatment.
Kin17 is a gene that is highly conserved across evolution. The
structures of kin17 and E. coli RecA proteins share an antigenic
determinant that is located in the core of kin17 protein and in the C-
terminal end of RecA protein [3]. Kin17 is ubiquitously expressed in
mammals and is associated with very important physiological
functions. In humans, it is generally expressed at extremely low
levels inall tissues and organs, except for in heart, skeletal muscle and
testis [3]. Kin17 binds preferentially to the curved DNA found at hot-
spots of illegitimate recombination in eukaryotic chromosomes and
has a tandem SH3 domain that participates in RNA binding [4,5].
Kin17 was determined to be a component of a multiprotein DNA
replicationcomplexand tobe associated withmammalianreplication
origins, mRNA processing, transcription and cell cycle regulation
[6,7]. It also participates in the general response to genotoxic stress
and is increased following DNA damage produced by UVC or
ionizing radiation, depending on the integrity of the human global
genome repair machinery [3,8,9]. Kin17 acts as a DNA maintenance
protein and helps to overcome perturbations in DNA replication
produced by unrepaired lesions [10]. Breast cancer cells are
characterized by uncontrolled growth, unlimited replication potential
and accumulated DNA damage [11–13]; therefore, investigating the
function of kin17 in breast cancers could elucidate some of the
mechanisms driving breast cancer growth as well as the implications
of these mechanisms for treatment strategies.
In this study, we examined kin17 expression in benign and
malignant breast tumors. The strong kin17 expression that we
observed in neoplastic cells and advanced tumors suggested a
potential role for kin17 in breast tumorigenesis. Knockdown of kin17
inhibited DNA replication and repair,reduced tumor cell growth and
colony formation. Our work is the first to demonstrate that kin17
plays a significant role in breast cancer pathogenesis and progression.
Results
Kin17 expression in breast tumors and cells
To explore the function of kin17 in breast cancers, we first
investigated kin17 expression in breast tumor tissues and peritumoral
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including 40 benign breast diseases (BBD) samples, 22 ductal
carcinoma in situ (DCIS) samples and 65 invasive ductal carcinoma
(IDC) samples, by immunohistochemistry. Ninety percent (36 out of
40) of the BBD showed weak staining, while 81.8% (18 out of 22) of
DCIS expressed kin17 at low levels; 18.2% (4 out of 22) had higher
levels. Notably, 43.1% (28 out of 65) of the IDC samples displayed
very strong nuclear staining and weak cytoplasmic staining (Table 1,
Figure 1A and Figure S1). Kin17 expression was significantly higher
in IDC than inBBD(p=0.0001)or DCIS tissues (p=0.036).InDCIS
tissues, the kin17 expression was slightly higher than in benign lesions;
however, there was no statistical differences between the two
(p=0.601). In contrast, the peritumoral epithelium displayed very
weak or negative staining (Figure 1A). Thus, the kin17 immuno-
staining in IDC was stronger than that in their peritumoral
counterparts (p=0.0001, Table 1). It seems that kin17 expression is
markedly up-regulated in breast cancers. To further confirm our
hypothesis, we compared kin17 expression in IDC tissues and their
peritumoral counterparts by western blot. We found that the kin17
expression level was significantly higher in tumors than in their
peritumoral counterparts (Figure 1B).
We also examined kin17 expression in breast epithelial cells. We
collected six types of breast cells, including four breast cancer cell
lines (MDA-MB-231, SKBr-3, BT474 and MCF-7), the immor-
talized non-tumorigenic cell line MCF-10A and the normal breast
epithelial cell Hs578Bst. Kin17 expression was extremely low in
Hs578Bst cells, while all four breast cancer cell lines displayed high
kin17 expression. The MCF-10A cells had a slightly higher level of
kin17 than the Hs578Bst cells, but this level was still markedly
lower than that in the four cancer cells (Figure 1C). In addition, we
found that kin17 was weakly expressed in vascular endothelial cells
in benign tumors and DCIS tissues but strongly expressed in the
vascular endothelial cells within IDC tissues (p=0.011, Figure S2).
It seems that kin17 expression was elevated in the vascular
endothelial cells located in malignant tumor tissues.
Association of kin17 expression with clinicopathologic
parameters
We reviewed the clinical characteristics of 65 patients with IDC
and examined the correlation of baseline characteristics with the
kin17 expression level. Kin17 expression level was significantly
associated with tumor grade (p=0.049, Table 2), luminal B
subtype (ER
+PR
+HER2
+, p=0.016) and Ki-67 expression
(p=0.046), but there were no significant association with age,
tumor size, tumor stage, estrogen receptor (ER) status, HER2
status or VEGF expression by univariate analysis (Table 2). To
further confirm the association between kin17 and Ki-67, frozen
IDC tissues were used for dual-labeled immunofluorescence
analysis with kin17 and Ki-67 antibodies. Similar to Ki-67,
kin17 was mostly nuclear located and strongly stained. Almost all
of the Ki-67-positive cells were kin17-positive (Figure 1D). The
same result was obtained in MDA-MB-231 cells, where kin17 and
Ki-67 were obviously co-expressed in the nucleus (Figure 1D). Ki-
67 is regarded as a marker for cell proliferation [14], so co-
expression of kin17 and Ki-67 in tumor tissues and cells suggests
that kin17 may also be related to cellular proliferation.
In addition, we also found a significant association between
kin17 expression and progesterone receptor (PR) expression
(p=0.046) as well as p53 mutation status (p=0.017). The
relationship among these factors needs to be further explored.
Kin17 is associated with cell proliferation, DNA
replication, cell cycle progression and the regulation of
cell morphology
In order to analyze the effects of kin17 on proliferative and
morphogenic phenotypes of breast epithelial cells and breast
cancer cells, we knocked down endogenous kin17 in MDA-MB-
231 (Figure 2A) and BT474 cells (Figure 2B) with siRNA_kin17.
Kin17 knockdown significantly inhibited the proliferation of
MDA-MB-231 (p,0.01) and BT474 cells (p,0.05), however,
had little effect on the proliferation of MCF-10A cells (Figure S3).
After knockdown of kin17, the colony number in soft agar was
decreased by 2.0 fold in MDA-MB-231 and 2.7 fold in BT474 cells
(p,0.05 and p,0.01, respectively). To investigate the mechanisms
underlying altered cell growth, EdU retention assays were
performed to examine the regulatory effect of kin17 on DNA
replication. Following transfection with siRNA_kin17, the per-
centage of EdU-positive cells was reduced in MDA-MB-231 and
BT474 cells compared to the controls (Figure 2C). Moreover, the
MDA-MB-231 and BT474 cells that were transfected with
siRNA_kin17 had a smaller part of the population in G0-G1
phase and an enhanced proportion in S phase (Figure 2D). It
seems that knockdown of kin17 resulted in cells that were blocked
in S phase and could not enter into G2 phase for cell division.
pEGFP-N1-kin17 was transfected into MCF-10A cells to
investigate the effect of kin17 on non-tumorigenic cells. Our
results showed that the proliferative rate of MCF-10A
mock was
similar to parental cells. While MCF-10A
kin17 cells showed a
higher proliferative capacity, as determined by the EdU retention
assay, compared to MCF-10A
mockcells in 2-dimensional (2-D)
cultures (Figure 2C and Figure 2E). Thus up-regulation of kin17
promoted the proliferation of breast non-tumorigenic cells. MCF-
10A
mock cells formed branching tubules and lumen in 3-D
matrigel cultures. However, MCF-10A
kin17 cells proliferated
quickly and rarely formed branching tube-like and luminal
structures. The small structures formed by MCF-10A
kin17 cells
never produced outgrowths that reached the size generated by
MCF-10A
mock cells (Figure 2F). Additionally, up-regulation of
kin17 increased ERK1/2 autophosphorylation and cylin D1
expression in MCF-10A and BT474 cells. While kin17 knockdown
decreased ERK1/2 autophosphorylation and cyclin D1 expression
in BT474 cells. However, ERK1/2 autophosphorylation and
cyclin D1 expression did not change when kin17 expression was
down-regulated in MCF-10A cells (Figure 2G and Figure 2H).
Table 1. Association between kin17 staining and groups of
breast disease.
Kin17 expression
Groups n (%) Low High P value
BBD 40(100) 36(90.0) 4(10.0) 0.0002
a*
DCIS 22(100) 18(81.8) 4(18.2)
IDC 65(100) 37(56.9) 28(43.1)
BBD vs. IDC 0.0001
b*
BBD vs. DCIS 0.601
c
DCIS vs. IDC 0.036
b*
Peritumoral tissues in IDC 52(100) 51 (98.1) 1 (1.9) 0.0001
b*
Intratumoral tissues in IDC 65(100) 37 (56.9) 28 (43.1)
Abbreviation: BBD, benign breast diseases; DCIS, Ductal carcinoma in situ; IDC,
Invasive ductal carcinoma.
aCochran-Mantel-Haenszel test,
bPearson Chi-Square test,
cContinuity correction test,
*statistically significant.
doi:10.1371/journal.pone.0025343.t001
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breast cancer cells
DNA damage is elevated in cancer cells due to carcinogenic
exposure, telomere shortening and hypoxia [15]. An increased
number of DNA lesions results in cell cycle arrest and cell death
due to the activation of DNA damage repair pathways [11]. We
hypothesized that elevation of kin17 would be necessary for DNA
repair in breast cancer cells. In this study, knockdown of kin17
resulted in DNA damage in both MCF-10A and BT474 cells.
However, more DNA damage was detected in the BT474 than in
the MCF-10A cells after kin17 was knocked down (Figure 3A). We
also treated cells with adriamycin (ADM), an anticancer drug that
is commonly used in breast cancer, to induce DNA damage. The
main forms of DNA damage induced by ADM are DNA double-
strand breaks, DNA single strand breaks, alkali labile sites, and
ADM–DNA adducts [16,17]. Alkaline comet assay has been
testified as an effective method to detect the DNA damage induced
by ADM [18,19]. Compared to the cells without ADM treatment,
a strong induction of DNA damage was detected in the ADM-
treated cancer cells, and more DNA damage appeared in the
BT474 than in the MCF-10A cells (Figure 3B). Furthermore,
siRNA_kin17-transfected breast cancer cells were much more
sensitive to ADM treatment (Figure 3C and Figure 3D). However,
kin17 silencing had no abvious effect on the chemosensitivity to
ADM in MCF-10A cells (Figure 3D). In parallel with DNA
damage, kin17 expression in MCF-10A and BT474 increased after
ADM treatment (Figure 3E).
Kin17 is required for EGF-stimulated cell growth
Epidermal growth factor (EGF) is an important growth factor
associated with cell proliferation and tumorigenesis in breast
cancer [20,21]. To determine if kin17 plays a role in the increased
cell proliferation caused by EGF, we knocked down kin17 and
then stimulated cells with EGF. Compared to the cells transfected
Figure 1. Kin17 expression in clinical breast tumors and cell lines. (A) Kin17 expression in BBD, DCIS and IDC tissues. The negative controls
for each tissue did not show staining (Figure S1). Scale bars=30 mm. (B) Western blot of kin17 in IDC tissues and peritumoral tissues. (C) Western blots
of kin17 in breast cancer cells and normal cells. The expression status of ER, PR and HER-2, in addition to the p53 mutation status, is listed for each cell
type [37]. (D) Dual staining of kin17 and Ki-67 in clinical IDC samples and MDA-MB-231 cells. Scale bars=30 mm.
doi:10.1371/journal.pone.0025343.g001
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siRNA_kin17 (Figure 4A). In addition, stimulation with EGF
resulted in an elevation in kin17 expression in MDA-MB-231,
BT474 and MCF-10A cells (Figure 4B). These results suggest that
kin17 is required for proliferation signaling initiated by EGF and
that EGF can elevate kin17 expression.
Discussion
Previous work has shown that human fibroblasts immortalized
with SV40 have an elevated level of kin17 protein compared to
normal diploid human fibroblasts [22]. In this study, we found that
kin17 expression is dramatically increased in clinical breast cancer
samples and breast cancer cells. In clinical samples, kin17
expression was significantly higher in IDC than in BBD and DCIS
tissues. In breast cell lines, kin17 expression was higher in
immortalized MCF-10A cells compared to normal Hs578Bst breast
cells. Importantly, kin17 expression was higher in breast cancer cells
compared to Hs578Bst and MCF10A cells. These results suggest
that kin17 expression gradually increases as breast cancer advances
from early- to late-stage disease. Additionally, increased kin17
expression was not only a consequence of the immortalized
phenotype, but it was also associated with tumorigenesis.
Kannouche et al. reported that serum-stimulated mouse
fibroblasts displayed a 5-fold higher expression of kin17 mRNA
and increased cell growth compared to the cells without serum
stimulation [23]. Our results agree with this study, and several lines
of evidence suggest that up-regulation of kin17 is essential for
mitogenesis. First, the level of kin17 expression was significantly
associated with breast cancer grade and Ki-67 expression. High-
grade breast cancer grows quickly and aggressively, and Ki67 serves
as a marker of cell proliferation. Thus, elevated kin 17 expression is
likely associated with breast cancer cell proliferation. Second,
suppression of kin17 blocked cell cycle progression and inhibited
growth in breast cancer cells. Finally, up-regulation of kin17 in
breastepithelialcellspromotedcellproliferationandinfluencedcell-
cell interactions and differentiation. Collectively, these data suggest
a role for kin17 in cellular proliferation.
Kin17 appears to play a central role in DNA replication and
repair. Kin17 colocalizes with multiple replication proteins,
including RPA, PCNA and DNA polymerase-a [7]. Specific
monoclonal antibodies that are targeted against kin17 reduce
cellular replication activity [7]. UVC irradiation induces the
nucleoplasmic redistribution of kin17 protein, indicating a link
between the intranuclear distribution of kin17 protein and the
DNA damage response [3]. c-irradiation increases the amount of
kin17 protein bound to DNA and localizes kin17 protein to large
nucleoplasmic foci [10]. Breast cancer cells exhibit replicative
immortality [13] and a high level of endogenous replication lesions
[12]. Our results showed that knockdown of kin17 in breast cancer
cells inhibited DNA replication, aggravated DNA damage and
blocked cells in the S phase of the cell cycle. Elevated kin17
expression appears to be required for DNA replication and repair
and to prevent cell cycle arrest.
The signaling pathway through which kin17 promotes cell
proliferation and tumorigenesis is unknown. Cyclin D1 is one of the
key regulators of the G1/S transition [24], and gene amplification
or overexpression of cyclin D1 is associated with cell growth and
tumorigenesis in breast cancer [25]. Cyclin D1 expression is
induced by various growth factors that are activated via the Ras/
MEK/ERK pathway [26]. We found that kin17 increased cyclin
D1 protein expression and constitutive phosphorylationof ERK1/2
in MCF-10A and BT474 cells. Suppression of kin17 blocked cell
cycle progression and decreased the expression of cyclin D1 and
ERK1/2 activity in breast cancer cells. These results suggest that
ERK1/2 and cyclin D1 may be involved in the kin17 signaling
cascade.p53mutationshavebeenidentified inmanytypesofcancer
[27], and such mutations serve as the most powerful prognostic
Table 2. Association between clinicopathologic variables and
kin17 expression in the 65 patients with IDC.
Kin17 expression
Variales n(%) Low High P value
Age — yr Mean 43.5 43.567.7 43.568.5 0.8945
a
Tumour size —n(%) Mean 30.6 mm
#30.6 mm 42 (64.6) 24 (64.9) 18 (64.3) 0.961
b
.30.6 mm 23 (35.4) 13 (35.1) 10 (35.7)
lymph nodes metastasis
No 41(63.1) 25(67.6) 16(57.1) 0.388
b
Yes 24(36.9) 12(32.4) 12(42.9)
Tumour grade—n(%)
1 14 (21.5) 12 (32.4) 2 (7.1) 0.049
b*
2 35 (53.9) 17 (46.0) 18 (64.3)
3 16(24.6) 8(21.6) 8(28.6)
Tumor stage—n(%)
I 15 (23.1) 10 (27.0) 5 (17.9) 0.658
b
II 40 (61.5) 22 (59.5) 18 (64.2)
III 10(15.4) 5(13.5) 5(17.9)
HER2 status—n(%)
Negative 25 (38.5) 15 (40.5) 10 (35.7) 0.692
b
Positive 40 (61.5) 22 (59.5) 18 (64.3)
Luminal A(ER+PR+HER22)—n(%)
No 52(80.0) 30(81.1) 22(78.6) 0.802
b
Yes 13(20.0 7(18.9) 6(21.4)
Luminal B(ER+PR+HER2+)—n(%)
No 51(78.5) 33(89.2) 18(64.3) 0.016
b*
Yes 14(21.5) 4(10.8) 10(35.7)
HER2 overexpression subtype (ER2PR2HER2+)—n(%)
No 50 (76.9) 30 (81.1) 20 (71.4) 0.360
b
Yes 15 (23.1) 7 (18.9) 8 (28.6)
Basal-like subtype (ER2PR2HER22)—n(%)
No 54(78.5) 29(78.4) 25(89.3) 0.408
c
Yes 11(21.5) 8(21.6) 3(10.7)
p53 status—n(%)
Wild 43 (66.2) 29 (78.4) 14 (50) 0.017
b*
Mutant 22 (33.8) 8 (21.6) 14 (50)
VEGF expression—n(%)
Low 32 (56.1) 16 (51.6) 16 (61.5) 0.452
b
High 25 (43.9) 15 (48.4) 10 (38.5)
Ki-67 status—n(%)
Negative 17 (34.7) 12 (48.0) 5 (20.8) 0.046
b*
Positive 32 (65.3) 13 (52.0) 19 (79.2)
aMann-whitney u test,
bPearson Chi-Square test,
cContinuity correction test,
*statistically significant.
doi:10.1371/journal.pone.0025343.t002
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PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25343Figure 2. Association of kin17 expression with cell proliferation, colony formation, DNA replication and cell cycle progression.
MDA-MB-231 (A) and BT474 cells (B) transfected with siRNA_kin17 showed reduced growth rate and colony formation compared to the controls.
* p,0.05, ** p,0.01. (C) Knockdown of kin17 expression inhibited DNA replication in MDA-MB-231 and BT474 cells compared to controls as
determined by the EdU incorporation assay. Elevated expression of kin17 increased DNA replication in MCF-10A cells. (D) Cell cycle phase
distributions were analyzed in a FACScalibur flowcytometer. These experiments were repeated 3 times, and the symbols represent the mean values
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increased kin17 expression and p53 mutations in our study would
strongly suggest that kin17 is involved in breast cancer progression.
In recent years, a host of new rationally designed, molecularly
targeted cancer therapies have been introduced as novel
treatments, with the aims of improving the cure rate and reducing
cytotoxicity in normal cells [29]. Breast cancer is a heterogeneous
disease, with various subtypes exhibiting different susceptibilities to
anticancer drugs. Therefore, therapies targeting specific breast
cancer subtypes are recommended for effective treatment [30]. ER
or PR positive patients show better responses to hormonal therapy
than ER/PR negative patients [31], and the HER-2 monoclonal
antibody trastuzumab has demonstrated efficacy in patients
overexpressing HER-2 [32]. However, only 20%–30% of breast
cancers are HER-2 positive, and some of the patients overex-
pressing HER-2 exhibit resistance to trastuzumab [33]. Triple-
negative (ER
2PR
2HER2
2) breast cancer patients, which ac-
counts for 10–20% of all breast cancers, are usually of high
histological grade and are accompanied by aggressive clinical
symptoms, with shorter time to recurrences and death; these
patients lack effective tailored therapies [34]. Interestingly, triple-
negative patients frequently express EGFR [35]. EGFR signaling
plays an important role in cell proliferation and tumorigenesis in a
variety of cancers, including breast cancer [36]. Overexpression of
EGFR protein occurs in 16–36% of breast cancers. Several
therapies targeting EGFR (cetuximab, gefitinib and erlotinib) are
in clinical use for advanced breast cancer. However, most of the
clinical trials have not succeeded [36]. In the present study, MDA-
MB-231 cells are triple-negative [33], and BT474 cells are
ER
+PR
+HER2
+[37], down-regulation of kin17 inhibited cell
growth and increased chemosensitivity to ADM in both MDA-
MB-231 and BT474 cells, suggesting that therapy that targets
kin17 is not limited by clinical immunophenotype. Moreover,
silencing kin17 expression inhibited proliferation signaling initiat-
ed by EGF. Thus, we proposed that combination of kin17
knocking down with ADM treatment would reduce the dose of
ADM, so as to lessen the drug resistance and toxicity of ADM in
conventional treatment. In addition, kin17 knockdown displayed
weak inhibition on proliferation of MCF-10A, and kin17 silencing
showed little effect on ERK1/2 autophosphorylation, cyclin D1
expression and chemosensitivity to ADM in MCF-10A cells. Thus,
kin17 silencing would be promising for breast cancer treatment.
Furthermore, we show that kin17 is necessary for EGF-stimulated
cell growth, therefore, treatment targeting kin17 could be
combined with neutral EGFR antibody therapy to treat breast
cancer.
In conclusion, in the present study, we make the novel proposal
that kin17 could be a useful target for breast cancer therapy. This
serves as a first step in characterizing kin17 at the molecular level
using in vitro techniques. These data can be extended in vivo models
to further elucidate the role of kin17 in cell proliferation and
carcinogenesis.
Materials and Methods
Patients and specimens
Sixty-five IDC samples, 22 DCIS samples and 40 BBD samples
were obtained and pathologically confirmed at the Guangdong
Women and Children’s Hospital and Health Institute. The 127
patients from whom the samples were derived underwent curative
resection between 2003 and 2009. The clinical characteristics of all
these patients are summarized in Table 2. Clinical stages were
classified according to the International Union against Cancer.
Fresh IDC and peritumoral tissues (at least 3 cm away from the
tumor margin) from 4 patients were used for kin17 expression
analysis. Frozen tumor tissues from 12 patients with IDC were
used for the double-labeled immunofluorescence analysis. All
samples were anonymously coded in accordance with local ethical
guidelines, and written informed consent was obtained. This study
was approved by the Review Board of Guangdong Women and
Children’s Hospital and Health Institute.
Immunohistochemistry
Paraffin sections (4 mm thick) were deparaffinized and rehy-
drated followed by immersing in 3% H2O2 to quench endogenous
peroxidase activity. Then, the sections were treated with 0.01 M
citrate buffer (pH 6.0) and blocked with 5% normal goat serum
followed by incubation with monoclonal anti-kin17 antibody
(1:100; Santa Cruz, k58), monoclonal anti-VEGF antibody (1:100;
Dako), monoclonal anti-ki-67 antibody (1:100; Dako), monoclonal
anti-estrogen receptors antibody (1:100; Dako), monoclonal anti-
progestrone receptors antibody (1:100; Dako), polyclonal anti-
HER2 rabbit antibody (1:100; Dako), monoclonal anti-p53
antibody (1:100; Dako) overnight at 4uC, respectively. These
primary antibodies were diluted in PBS buffer containing 5%
normal goat serum. The negative control for each slide was
incubated with 5% normal goat serum without primary antibody.
The sections were then incubated with HRP-conjugated anti-
mouse or anti-rabbit IgG for 45 min at room temperature and
revealed with a ChemMate
TM Envision
TM Dectection Kit
(DAKO). The stained slides were scored by two investigators,
who were unaware of the clinical diagnosis, according to the
method described by Merritt W M et al [38]. A staining score
(intensity of staining6percentage of cells stained) of .100 was
defined as high expression and a staining score of #100 was
defined as low expression. The specificity and selectivity of kin17
antibody (K58) have been determined by Miccoli L [22] and Biard
DS [1].
Cell culture
The human breast cancer cell lines MDA-MB-231, BT474,
MCF-7 and Hs 578Bst were obtained from the cell bank of the
Chinese Academy of Sciences. SK-Br3 and MCF-10A were from
ATCC. BT474, SK-Br3 and MCF-7 cells were cultured in a
DMEM/F12 (1:1 mixture; Sigma) supplemented with 10% fetal
bovine serum (FBS, Hyclone), 100 U/ml penicillin and 100 mg/
ml streptomycin. MDA-MB-231 cells were grown in Leibovitz-15
(L-15) medium (Invitrogen) supplemented with 10% FBS.
Hs578Bst cells were cultured in DMEM/F12 supplemented with
10% FBS and EGF (30 ng/ml; Pepro Tech). Human MCF-10A
non-tumorigenic mammary epithelial cells were maintained in
DMEM/F-12 supplemented with 10% FBS, insulin (10 mg/ml,
Invitrogen), hydrocortisone (500 ng/ml; Sigma) and EGF (20 ng/
ml). MCF-10A cells are immortalized diploid cells that possess
normal epithelial characteristics [39]. Cultures were maintained at
37uC in a humidified atmosphere containing 5% CO2.
of triplicate tests (mean 6 SD). (E) Overexpression of kin17 following transfection with pEGFP-N1-kin17 promoted cell proliferation in MCF-10A cells.
Cells positive for the EGFP-N1-kin17 were designated MCF-10A
kin17, while cells transfected with pEGFP-N1 vector were designated MCF-10A
mock. (F)
Overexpression of kin17 disrupted acinar organization and blocked luminal clearance in MCF-10A cells. Western blotting analysis of
autophosphorylation of ERK1/2 (G) and cyclin D1 expression (H). The experiment was independently repeated at least 3 times.
doi:10.1371/journal.pone.0025343.g002
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Proteins from cells or fresh tissues were extracted in RIPA lysis
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100,
0.25% sodium deoxycholate, 0.1% SDS) containing a protease
inhibitor cocktail (Roche). Equal amounts of protein were separated
by SDS-PAGE and blotted onto PVDF Immobilon-P membranes
(GE Healthcare). After blocking, the membranes were probed with
an anti-kin17 mAb (1:500) overnight at 4uC. A b-actin mAb (1:500;
Santa Cruz) was used as a control for loading. Thereafter,
membranes were incubated with HRP-conjugated anti-mouse IgG
(1:5000) for 45 min at room temperature. The reactions were
visualized using enhanced chemiluminescence (GE Healthcare).
Images were captured with ImageQuant RT ECL (GE Healthcare),
and densitometry analysis was performed using ImageQuant TL 7.0
Image Analysis Software (GE Healthcare). Only samples run in the
same gel were compared.
Dual-labeled immunofluorescence
The frozen IDC tissue samples or MDA-MB-231 cells were
incubated with a mixture of the anti-kin17 antibody (1:100) and a
Ki67 antibody (1:100; Dako) overnight at 4uC. After incubation
with a mixture of Alexa Fluor 488–conjugated goat anti-rabbit
antibody (1:400; Invitrogen) and Alexa Fluor 594–conjugated goat
anti-mouse antibody (1:400; Invitrogen), the slides were counter-
stained with 0.2 mg/ml 49,6-diamidine-29-phenylindole dihydro-
chloride (DAPI) and mounted in fluorescence mounting medium
(Dako). Specimens were examined by a laser scanning confocal
microscopy (Leica, TCS Sp5).
Plasmid construction
The full-length Kin17 ORF (nt 49–1230; GenBank accession
number NM_ 012311) was amplified by PCR using PK3-Kin17,
which was a kind gift from Dr. Miccoli (CEA, France). The
primers were as follows: forward, 59- ATACTCGAGATGGG-
GAAGTCGGATTTTC -39; reverse, 59- GCAAGCTTGGCAA-
GTTTAGAAATGTCTTCAT -39. After digestion with Xho I and
Hind III, the PCR product was inserted into the Xho I and Hind III
sites of the pEGFP-N1 expression vector (Clontech), and the
resulting construct was termed pEGFP-N1-Kin17. Restriction
enzyme digestion and DNA sequencing were used to confirm the
sequence and orientation of the recombinant construct.
Cell transfection
Cells were transfected with siRNA_kin17 (sc-45958, Santa
Cruz) or pEGFP-N1-kin17 using Lipofectamine 2000 Transfec-
tion Reagent (Invitrogen) according to the manufacturer’s
instructions. Control siRNA (sc-37007, Santa Cruz) or empty
pEGFP-N1 vector were transfected as respective controls.
Figure 3. Kin17 is associated with DNA damage in breast cells. (A) Knockdown of kin17 increased DNA damage in MCF-10A and BT474 cells.
(B) The cells were treated with ADM at the indicated concentrations for 24 hr, and analyzed using the comet assay kit. (C) Representative images of
DNA damage in BT474 cells. The cells were transfected with siRNA_kin17 or treated with ADM (0.3 mg/ml) for 24 hr. Scale bars=50 mm. (D) The effect
of kin17 knockdown on the chemosensitivity to ADM in MCF-10A, BT474 and MDA-MB-231 cells (p,0.05). (E) The cells were treated with ADM at the
indicated concentrations for 48 hr, and then kin17 expression was analyzed by western blot.
doi:10.1371/journal.pone.0025343.g003
Figure 4. Kin17 is associated with an EGF response. (A) Kin17 silencing inhibited EGF-stimulated cell growth in MCF-10A and BT474 cells.
p,0.05. (B) The cells were treated with recombinant human EGF for 48 hr, and kin17 expression was detected by western blot.
doi:10.1371/journal.pone.0025343.g004
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The cells were seeded in a 24-well plate at a density of 1610
4
cells/ml/well and then cultured for 6 days. Cells were trypsinized
and counted every 24 hr using a Coulter Counter (Beckman,
Z1).
3-D morphogenesis assay
The cells (2.5610
4/well) were mixed in matrigel (BD) and
added onto a 96-well plate containing an underlay of 50 ml
solidified matrigel. 150 ml of culture media was then added to all
wells. The phenotype of cells embedded in matrigel was
determined after cultivation for 15 days.
Soft agar colony formation
The cells (1610
4) were plated onto a 6-well plate containing 1%
base agar and 0.5% top agar. Plated cells were incubated at 37uC
for 21 days. The plates were then stained with crystal violet and
colonies containing more than 50 cells were counted using
ImageQuant TL 7.0 Image Analysis Software (GE Healthcare).
EdU retention assay
Dissociated cells were exposed to 25 mM of 5-ethynyl-29-
deoxyuridine (EdU, RiboBio) for 2 hr at 37uC, and then the cells
were fixed in 4% PFA. After permeabilization with 0.5% Triton-
X, the cells were reacted with 16 Apollo reaction cocktail
(RiboBio) for 30 min. Subsequently, the DNA contents of the cells
were stained with Hoechst 33342 for 30 min and visualized under
a laser scanning confocal microscopy (Leica, TCS Sp5).
Flow cytometry
Ethanol-fixed cells were incubated with RNase A (100 mg/ml)
and propidium iodide (PI, 50 mg/ml) for 30 minutes at 4uC. PI
fluorescence was measured in a FACScalibur flow cytometer (BD).
Data were collected from 10,000 single cell events, and cell cycle
phase distributions were calculated using MODFIT software
(Verity Software House).
Alkaline comet assay
The cells were transfected with siRNA_kin17 or treated with
adriamycin (ADM) at the indicated concentrations for 24 hr,
whereupon DNA damage was detected using CometSlide (Trevi-
gen, Gaithersburg, MD, USA) according to the manufacturer’s
instructions. After electrophoresis, we stained fragmented DNA
with SYBRH Green I and visualized it under a fluorescence
microscope (Nikon Eclipse Ti-U). Comet tails from 100 cells in each
group were documented, and the tail DNA content was calculated
using CASP Analysis Software (University of Wroclaw, Poland).
Statistical analysis
Baseline characteristics of patients and tumors as well as tumor
biology variables were compared using Student’s t-test (continuous
variables) and Chi-squared (x
2) tests (categorical variables). All
statistical tests and corresponding p-values reported were for two-
sided tests, and p values of less than 0.05 were considered
statistically significant. SPSS (version 12.0; Chicago, IL) was used
for all statistical analyses.
Supporting Information
Figure S1 Negative controls for immunohistochemical
staining in BBD, DCIS and IDC tissues. Scale bars=30 mm.
(TIF)
Figure S2 Kin17 expression in vascular endothelial cells
was detected by immunohistochemistry. Scale bars=30 mm.
(TIF)
Figure S3 Influence of kin17 knockdown on cell growth
of MCF-10A cells. (A) Western blot of kin17 expression in MCF-
10A cells transfected with siRNA_NC or siRNA_kin17. (B)
Growth curve of MCF-10A cells transfected with siRNA_NC or
siRNA_kin17. This experiment was repeated at least three times,
and the symbols represent the mean values of triplicate tests (mean
6 SD), p.0.05.
(TIF)
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